ES2168357T3 - Agonistas del receptor ep2 como agentes para disminuir la presion intraocular. - Google Patents

Agonistas del receptor ep2 como agentes para disminuir la presion intraocular.

Info

Publication number
ES2168357T3
ES2168357T3 ES95909222T ES95909222T ES2168357T3 ES 2168357 T3 ES2168357 T3 ES 2168357T3 ES 95909222 T ES95909222 T ES 95909222T ES 95909222 T ES95909222 T ES 95909222T ES 2168357 T3 ES2168357 T3 ES 2168357T3
Authority
ES
Spain
Prior art keywords
around
sub
link
carbon atoms
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95909222T
Other languages
English (en)
Inventor
David F Woodward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Sales LLC
Original Assignee
Allergan Sales LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
Application granted granted Critical
Publication of ES2168357T3 publication Critical patent/ES2168357T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA INVENCION SE REFIERE A ( (MAS MENOS) ) TRANS- 2-[[]-4(()1HIDROXIHEXILO()) FENILO[]]-5-OXOCICLOPENTANOHEPTANOICACIDO, Y ESTER Y DERIVADOS INSATURADOS DEL MISMO, DERIVADOS DE PROSTAGLANDINA. EN CONCRETO, LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE FORMULA (I), EN DONDE LOS ENLACES ONDULADOS INDICAN LA CONFIGURACION {AL} O {BE}, EL ENLACE DISCONTINUO REPRESENTA O UN ENLACE UNICO O UNO DOBLE, EL CUAL PUEDE SER UN ENLACE DOBLE CIS O TRANS Y R ES UN GRUPO DE HIDROCARBURO SATURADO O INSATURADO ACICLICO QUE TIENE DE 1 A ALREDEDOR DE 20 ATOMOS DE CARBONO, O (()CH{SUB,2}()){SUB,M}R{SUB,1}- EN DONDE M ES DE 0-10, Y R{SUB,1} ES UN ANILLO ALIFATICO QUE TIENE DESDE ALREDEDOR DE 3 A ALREDEDOR DE 7 ATOMOS DE CARBONO, O UN ANILLO DE ARILO O HETEROARILO QUE TIENE DE ALREDEDOR DE 4 A ALREDEDOR DE 10 ATOMOS DE CARBONO Y EN DONDE EL HETEROATOMO SE SELECCIONA DEL GRUPO QUE CONSTA DE N, O Y S. LOS COMPUESTOS DE LA PRESENTE INVENCION SON POTENTES HIPOTENSORES OCULARES, Y SON PARTICULARMENTE UTILES PARA ELTRATAMIENTO DE GLAUCOMA.
ES95909222T 1994-01-19 1995-01-09 Agonistas del receptor ep2 como agentes para disminuir la presion intraocular. Expired - Lifetime ES2168357T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/183,682 US5462968A (en) 1994-01-19 1994-01-19 EP2 -receptor agonists as agents for lowering intraocular pressure

Publications (1)

Publication Number Publication Date
ES2168357T3 true ES2168357T3 (es) 2002-06-16

Family

ID=22673876

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95909222T Expired - Lifetime ES2168357T3 (es) 1994-01-19 1995-01-09 Agonistas del receptor ep2 como agentes para disminuir la presion intraocular.

Country Status (7)

Country Link
US (1) US5462968A (es)
EP (1) EP0789687B1 (es)
JP (2) JP4275194B2 (es)
AU (1) AU685591B2 (es)
DE (1) DE69524446T2 (es)
ES (1) ES2168357T3 (es)
WO (1) WO1995019964A1 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2293325C (en) * 1997-05-09 2008-09-02 The Mount Sinai School Of Medicine Of The City University Of New York 8-iso-prostaglandins for glaucoma therapy
US6090847A (en) * 1997-11-21 2000-07-18 Allergan Sales, Inc. EP2 -receptor agonists as neuroprotective agents for the eye
US5877211A (en) * 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
EP1000619A3 (en) * 1998-06-23 2002-07-24 Pfizer Products Inc. Method for treating glaucoma
US6545045B1 (en) 1998-12-24 2003-04-08 Alcon Manufacturing, Ltd. Prostaglandin E agonists for treatment of glaucoma
EP1159266B1 (en) 1999-03-05 2004-11-03 Duke University C-16 unsaturated fp-selective prostaglandins analogs
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
MXPA04009036A (es) * 2002-03-18 2005-01-25 Pfizer Prod Inc Uso de agonistas del receptor ep4 selectivos para el tratamiento de la insuficiencia hepatica, perdida de permeabilidad del ductus arterioso, glaucoma o hipertension ocular.
JP2005534653A (ja) * 2002-06-06 2005-11-17 メルク フロスト カナダ アンド カンパニー 眼及び骨疾患の治療に於いてｅｐ４受容体作動薬として使用するための１，５−二置換イミダゾリジン−２−オン誘導体
JP2006021998A (ja) * 2002-07-18 2006-01-26 Ono Pharmaceut Co Ltd Ｅｐ２アゴニストを有効成分とする月経困難症治療剤
EP1545517A1 (en) * 2002-08-28 2005-06-29 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
DK1563846T3 (da) 2002-10-10 2012-12-17 Ono Pharmaceutical Co Endogene reparationsfaktorproduktionsfremmere
WO2004037786A2 (en) * 2002-10-25 2004-05-06 Merck Frosst Canada & Co. 2-pyrrolidones as ep4 receptor agonists
KR101077461B1 (ko) * 2003-02-11 2011-10-26 알러간, 인코포레이티드 안압 강하제로서의 10,10-디알킬 프로스탄산 유도체
JP4666257B2 (ja) 2003-07-25 2011-04-06 小野薬品工業株式会社 軟骨関連疾患治療剤
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
GB0329620D0 (en) * 2003-12-22 2004-01-28 Pharmagene Lab Ltd EP2 receptor agonists
US7858650B2 (en) 2004-10-22 2010-12-28 Ono Pharmaceutical Co., Ltd. Medicinal composition for inhalation
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
WO2006098918A2 (en) * 2005-03-10 2006-09-21 Allergan, Inc. Substituted gamma lactams as therapeutic agents
WO2006121822A1 (en) * 2005-05-06 2006-11-16 Allergan, Inc. USE OF β-LACTAMS FOR THE TREATMENTOF IBD AND GLAUCOMA
US7674786B2 (en) * 2005-05-06 2010-03-09 Allergan, Inc. Therapeutic β-lactams
EP1886693A4 (en) 2005-06-03 2010-03-03 Ono Pharmaceutical Co ACTIVE AGENT FOR REGENERATING AND / OR PROTECTING NERVES
WO2007115020A2 (en) * 2006-04-04 2007-10-11 Allergan, Inc. Therapeutic prostaglandin compounds for the treatment of glaucoma
US7439372B2 (en) 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
US20090016981A1 (en) 2006-05-03 2009-01-15 Allergan, Inc. Therapeutic compounds
US7491844B2 (en) 2006-05-04 2009-02-17 Allergan, Inc. Therapeutic cyclopentane derivatives
US7476755B2 (en) * 2006-05-04 2009-01-13 Allergan, Inc. Therapeutic compounds
US7557095B2 (en) * 2006-05-12 2009-07-07 Allergan, Inc. Therapeutic compounds
US7547727B2 (en) * 2006-05-22 2009-06-16 Allergan, Inc. Therapeutic cyclopentane derivatives
US7550448B2 (en) 2006-05-24 2009-06-23 Allergan, Inc. Therapeutic compounds
US7498447B2 (en) 2006-05-24 2009-03-03 Allergan, Inc. Therapeutic compounds
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
AU2008208042B2 (en) 2007-01-25 2014-02-27 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
US9365485B2 (en) 2007-01-25 2016-06-14 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
US8063033B2 (en) 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US7956051B2 (en) * 2008-01-24 2011-06-07 Allergan, Inc. Therapeutic amides and related compounds
US8633310B2 (en) * 2008-02-19 2014-01-21 Allergan, Inc. Therapeutic substituted lactams
US7964596B2 (en) 2008-03-07 2011-06-21 Allergan, Inc. Therapeutic compounds
US20090233921A1 (en) * 2008-03-11 2009-09-17 Allergan, Inc. Therapeutic cyclopentane derivatives
US7960379B2 (en) * 2008-03-14 2011-06-14 Allergan, Inc. Therapeutic compounds
US7732443B2 (en) * 2008-03-18 2010-06-08 Yariv Donde Therapeutic substituted cyclopentanes
US8198318B2 (en) * 2008-03-18 2012-06-12 Allergen, Inc. Therapeutic amides
US7956055B2 (en) * 2008-03-25 2011-06-07 Allergan, Inc. Substituted gamma lactams as therapeutic agents
AU2009239372B2 (en) 2008-04-24 2013-09-19 Allergan, Inc. Substituted gamma lactams as therapeutic agents
EP2288600A1 (en) * 2008-04-24 2011-03-02 Allergan, Inc. Substituted arylcyclopentenes as prostaglandin ep2 agonists
US7964634B2 (en) * 2008-04-24 2011-06-21 Allergan, Inc. Therapeutic compounds
BRPI0911543A2 (pt) * 2008-04-24 2015-10-13 Allergan Inc arilciclopentenos substituídos como agentes terapêuticos
WO2009137413A1 (en) * 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic cyclopentane derivatives
EP2285782A2 (en) * 2008-05-09 2011-02-23 Allergan, Inc. Therapeutic n-aryl or n-heteroaryl pyrazolidine and pyrazolidinone derivatives
US8569349B2 (en) * 2008-05-09 2013-10-29 Allergan, Inc. Therapeutic compounds
JP2011520807A (ja) 2008-05-09 2011-07-21 アラーガン インコーポレイテッド 治療用置換ヒダントイン類および関連化合物
US8541603B2 (en) * 2008-05-27 2013-09-24 Allergan, Inc. Substituted cyclopentanes or cyclopentanones as therapeutic agents
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US7985765B2 (en) 2008-08-20 2011-07-26 Allergan, Inc. Therapeutic substituted pyrroles
EP3828172A1 (en) 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
ES2733998T3 (es) 2012-10-29 2019-12-03 Cardio Incorporated Agente terapéutico específico de enfermedad pulmonar
CN105263494A (zh) 2013-03-15 2016-01-20 爱瑞制药公司 联合治疗
WO2014194209A1 (en) 2013-05-31 2014-12-04 Allergan, Inc. Substituted cyclopentenes as therapeutic agents
WO2015056504A1 (ja) 2013-10-15 2015-04-23 小野薬品工業株式会社 薬剤溶出性ステントグラフト
US9394273B2 (en) * 2014-05-15 2016-07-19 Allergan, Inc. Therapeutic prostaglandin receptor agonists
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
JP6907319B2 (ja) 2016-08-31 2021-07-21 アエリエ ファーマシューティカルズ インコーポレイテッド 眼科用組成物
JP2020515583A (ja) 2017-03-31 2020-05-28 アエリエ ファーマシューティカルズ インコーポレイテッド アリールシクロプロピル−アミノ−イソキノリニルアミド化合物
WO2020056345A1 (en) 2018-09-14 2020-03-19 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
DE3220156C2 (de) * 1982-05-28 1990-01-25 Heida Houston Tex. Thurlow Mit Metallgriffen, insbesondere Edelstahlgriffen, versehenes Koch- und Bratgeschirr mit Deckel
EP0569046B1 (en) * 1988-09-06 2002-11-13 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5034413A (en) * 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins

Also Published As

Publication number Publication date
DE69524446D1 (de) 2002-01-17
DE69524446T2 (de) 2002-06-27
JPH09509652A (ja) 1997-09-30
EP0789687A1 (en) 1997-08-20
AU1725795A (en) 1995-08-08
AU685591B2 (en) 1998-01-22
JP4275194B2 (ja) 2009-06-10
US5462968A (en) 1995-10-31
EP0789687B1 (en) 2001-12-05
JP2008214351A (ja) 2008-09-18
WO1995019964A1 (en) 1995-07-27

Similar Documents

Publication Publication Date Title
ES2168357T3 (es) Agonistas del receptor ep2 como agentes para disminuir la presion intraocular.
DE69311361D1 (de) Zusammensetzungen zur behandlung von glaukoma die prostaglandine und clonidinderivate enthalten
RU2291860C3 (ru) Производные 2-оксо-1-пирролидина, способ их получения и применения
ES2059491T3 (es) Derivados de indol con anillos condensados.
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
ES2094719T3 (es) Derivados de pirazol y herbicidas que los contienen.
PE20020720A1 (es) Derivados benzimidazol y piridilimidazol como ligandos para receptores gabaa
CO4650117A1 (es) Derivados de bencilsulfuro y proceso para su produccion .
FR2387968A1 (fr) Derives soufres du 1,2,4-triazole, utilisables comme additifs de lubrifiants
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
ES2107522T3 (es) 2-descarboxil-2-aminoalquil-prostaglandinas como agentes hipotensivos oculares.
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
ATE78031T1 (de) Prostaglandin-derivate zur behandlung von glaucoma oder augenueberdruck.
KR890006241A (ko) 설사약
ES2164366T3 (es) Derivados de la distamicina acriloil sustituidos, procedimiento de fabricacion asociado y su utilizacion como agentes antitumorales y antivirales.
FR2379581A1 (fr) Colorants fluorescents derives de la coumarine
MX9305093A (es) Nuevos derivadosindano-2 mercaptoacetilamina triciclicos 2-sustituidos, utiles como inhibidores de la encefalinasa.
ES2062202T3 (es) Derivado del indol.
ATE130603T1 (de) Oxalon und hypotensive 2-decarboxyl-2 azylthioalkyl prostagladin-derivate.
ES2103161B1 (es) Derivados de cicloheptimidazol, metodo de fabricacion de los mismos y agentes terapeuticos que contienen estos compuestos.
FR2361326A1 (fr) Derives de cyclohexane utiles comme agents odoriferants
ES2063224T3 (es) Benzoxacinil-pirazoles, su produccion y su uso.
AR034400A1 (es) Piranoindoles, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de glaucoma
ATE196464T1 (de) Benzol-derivate, verwendbar für ischämische erkrankungen
ES2195500T3 (es) Dereivados del 2-indanometanol y su utilizacion a titulo de ingredientes perfumantes.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 789687

Country of ref document: ES